Homogeneous assay for monoclonal antibody detection in serum
Homogeneous assay for monoclonal antibody detection in serum
批准号:
8007141
负责人:
Manuel E Ruidiaz
金额:
$3.18万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-22 至 2011-12-31
关键词:
AccountingAcuteAddressAffinityAntibodiesAntibody TherapyAntigensAntineoplastic AgentsAvidityBindingBiologicalBiological AssayBiologyBlood specimenCancer PatientChronic Lymphocytic LeukemiaClinical ResearchClinical TreatmentComplexCystineDetectionDevelopmentDevicesDiagnostic or Prognostic FactorDiseaseDisulfide LinkageDoseDrug KineticsEffectivenessEnergy TransferFluorescenceFluorescence PolarizationGoalsHealthIndividualInjection of therapeutic agentLabelLeadLysineMalignant NeoplasmsMeasurementMeasuresMedicalMedicineMetabolismMonoclonal AntibodiesMorphologic artifactsNatureOverdosePatientsPeptide antibodiesPeptidesPhage DisplayPharmaceutical PreparationsPharmacotherapyPhaseProbabilityReagentRegimenReporterReportingResearchResistanceRotationRouteSamplingScheduleSchemeSerumSolutionsSpecificitySpeedSystemTechniquesTechnologyTestingTherapeutic AgentsTumor BurdenUncertaintyalemtuzumabbasecancer therapydesigndosagedrug developmentfluorophoreimprovedmimeticsmodel developmentnovelpeptide Ppoint of carepre-clinicalresponserituximabtechnology developmenttherapeutic proteintumor
中文摘要
描述(由申请人提供):本申请的长期目标是开发一种设备,对患者血清中抗体药物的状态提供快速护理点分析。抗体在生物检测中作为治疗剂和试剂有着广泛的应用。检测和量化抗体的能力是其许多应用中的一个关键方面。生物样本中抗体和其他蛋白质疗法的检测在需要确定诊断和/或预后因素的医疗应用中至关重要。然而,确定特定抗体的药代动力学可能是有问题的,特别是当检测是在高背景下进行的时候,例如在生物样本中。有两个关键的应用程序。(1)抗体药物的给药时间表和给药途径是在许多不确定的情况下制定的,通常通过临床前和临床研究加以改进,在这些研究中,迫切需要简单和可靠的药代动力学分析。特定抗体靶点的特定生物学也可能导致常规剂量递增范例的额外并发症。(2)如果每次注射后根据患者血清中检测到的抗体水平来调整每个患者的抗癌药物剂量,将会更加经济和安全,因为传统的给药方案没有考虑到患者代谢和肿瘤负荷的巨大变化。一种增强的检测系统已经开发出来,可以快速确定血液样本中存在的抗体药物的浓度。本研究将致力于这项技术的发展,以进一步提高检测的可靠性和灵敏度。Alemtuzumab(抗CD52)将被用作检测改进的开发模型。目前它通常用于慢性淋巴细胞白血病(CLL)患者。这项研究将分为三个阶段。1)一阶均相抗体检测方法的建立。2)发展了一种新的高灵敏度检测增强技术。3)确定和实施检测试剂盒,以便进行护理点检测和分析。
英文摘要
DESCRIPTION (provided by applicant): The long term goal of this application is to develop a device to provide rapid point of care analysis of the state of antibodies drugs within patient serum. Antibodies are widely used in a variety of applications, as therapeutic agents and reagents in biological assays. The ability to detect and quantify antibodies is a key aspect in many of their applications. Detection of antibodies and other protein therapeutics in a biological sample is critical in medical applications requiring determination of diagnostic and/or prognostic factors. However, determining the pharmacokinetics of a particular antibody can be problematic, especially when the detection is performed against a high background, as in a biological sample. There are two key applications. (1) Dosing schedules and routes of administration for antibody drugs are developed with many uncertainties and are often refined through pre-clinical and clinical studies where the need for simple and reliable pharmacokinetic assays is acute. The specific biology of a given antibody target can also lead to additional complications from the conventional dose escalation paradigm. (2) Antibody cancer drugs would be more economical and safer if the dose for each patient could be adjusted based on the antibody levels detected in the serum of the patient after each injection since the great variability in patient metabolism and tumor load is not captured in traditional dosage schemes. An enhanced detection system has been developed that can rapidly determine the concentration of antibody drugs present from blood samples. This research will focus on the development of this technology to further improve the assay in terms of reliability and sensitivity. Alemtuzumab (anti-CD52) will be used as a development model for assay refinement. It is currently used commonly in patients with chronic lymphocytic leukemia (CLL). The research will consist of three phases. 1) Development of a first order homogeneous assay for measurement of antibody. 2) Development of a novel enhancement technique for high sensitivity detection. 3) Determination and implementation of an assay kit to allow for point of care detection and analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金